PRDM16 and acute myeloid leukemia: Therefore, an overall trend for adverse outcome in NPM1-mutant AMLs with PRDM16 overexpression may be an epiphenomenon, reflecting the underlying genetic features rather than an independent driver of AML pathogenesis.